Monitor final EMA approval decision (typically follows CHMP positive opinion within 2-3 months) and subsequent EU launch timing; watch for FDA decision on the BLA submitted September 2025 as the next major catalyst for US market access.
Price Chart
Executive Summary
Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for FREHEMGO (denecimig), a first-in-class factor VIIIa mimetic for haemophilia A with or without inhibitors, offering monthly, biweekly, and weekly dosing in a pre-filled pen. The recommendation is based on the FRONTIER trial program showing significantly reduced annualized bleeding rates and a favorable safety profile, including direct switching from emicizumab. Novo expects to launch in the first European countries in Q4 2026 and broadly across the EU starting early 2027.
Key Facts
- CHMP recommended EU approval of FREHEMGO (denecimig) for haemophilia A with or without inhibitors in adults and children
- First FVIIIa mimetic offering once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen
- Pivotal FRONTIER 2 trial showed denecimig significantly reduced annualised bleeding rate vs prior clotting factor prophylaxis and on-demand treatment
- FRONTIER 3 results in children <12 years consistent with efficacy in adolescents and adults
- FRONTIER 5 trial showed no new safety signals after direct switching from emicizumab to denecimig, with clear preference for the denecimig device
- Novo expects to launch FREHEMGO in first European countries in Q4 2026 and broadly across EU starting early 2027
- Denecimig was submitted to the FDA for review in September 2025 via a BLA
Financial Impact
Positive opinion from CHMP is a major regulatory milestone for a first-in-class haemophilia A treatment with differentiated dosing flexibility; commercial launch in EU expected Q4 2026, expanding Novo's haemophilia franchise beyond existing portfolio
Risk Factors
- Final EMA approval is not guaranteed despite CHMP positive opinion
- Competition from existing haemophilia A treatments including emicizumab (Hemlibra) and other factor VIII therapies
- Pricing and reimbursement negotiations across EU member states may affect commercial uptake
- US FDA review outcome remains pending and could differ from EU decision
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006088 |
| Document: 0001171843-26-006088-index-headers.html | 0001171843-26-006088 |
| Document: 0001171843-26-006088-index.html | 0001171843-26-006088 |
| Document: 0001171843-26-006088.txt | 0001171843-26-006088 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $39.00 | awaiting T+20 | — | $38.65 (−0.87%) |
Oct 19, 2026 8d ago | 6-K | $38.42 | awaiting T+20 | — | $38.65 (+0.61%) |
Oct 13, 2026 14d ago | 6-K | $38.06 | awaiting T+20 | — | $38.65 (+1.56%) |
Oct 6, 2026 21d ago | 6-K | $37.53 | awaiting T+20 | — | $38.65 (+3.00%) |
Sep 28, 2026 29d ago | 6-K | $38.71 $38.95 | ▲ +0.61% | ▲ +0.64% | $38.65 (−0.14%) |
Sep 23, 2026 4w ago | Court Ruling | $38.62 $39.43 | ▲ +2.10% | ▲ +2.52% | $38.65 (+0.09%) |
Sep 21, 2026 5w ago | 6-K | $39.80 $38.42 | ▼ −3.47% | ▼ −2.56% | $38.65 (−2.88%) |
Sep 17, 2026 5w ago | 6-K | $43.19 $39.22 | ▼ −9.19% | ▼ −10.40% | $38.65 (−10.50%) |
Sep 15, 2026 6w ago | 6-K | $42.53 $38.06 | ▼ −10.51% | ▼ −13.23% | $38.65 (−9.11%) |
Sep 9, 2026 6w ago | 6-K | $44.56 $38.26 | ▼ −14.14% | ▼ −16.08% | $38.65 (−13.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers